MX2024006718A - Antagonistas del receptor muscarínico m4 de acetilcolina. - Google Patents
Antagonistas del receptor muscarínico m4 de acetilcolina.Info
- Publication number
- MX2024006718A MX2024006718A MX2024006718A MX2024006718A MX2024006718A MX 2024006718 A MX2024006718 A MX 2024006718A MX 2024006718 A MX2024006718 A MX 2024006718A MX 2024006718 A MX2024006718 A MX 2024006718A MX 2024006718 A MX2024006718 A MX 2024006718A
- Authority
- MX
- Mexico
- Prior art keywords
- antagonists
- acetylcholine receptor
- muscarinic acetylcholine
- compounds
- octahydrocyclopenta
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- 102000000413 Muscarinic acetylcholine receptor M4 Human genes 0.000 title 1
- 108050008897 Muscarinic acetylcholine receptor M4 Proteins 0.000 title 1
- -1 (6-(4-(trifluoromethyl)pyridin-3-yl)pyridazin-3-yl)octahydrocyclopenta[c]pyrrol-5-amine Chemical compound 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 abstract 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163284750P | 2021-12-01 | 2021-12-01 | |
| PCT/US2022/051493 WO2023102100A1 (en) | 2021-12-01 | 2022-12-01 | Antagonists of the muscarinic acetylcholine receptor m4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024006718A true MX2024006718A (es) | 2024-08-09 |
Family
ID=84943708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024006718A MX2024006718A (es) | 2021-12-01 | 2022-12-01 | Antagonistas del receptor muscarínico m4 de acetilcolina. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250145595A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4441046A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024543973A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240112343A (cg-RX-API-DMAC10.html) |
| CN (2) | CN116669737A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022400780A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3241298A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL313219A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024006718A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023102100A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3651762B1 (en) | 2017-07-12 | 2024-07-03 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| JP7270989B2 (ja) | 2017-10-20 | 2023-05-11 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| US12319701B2 (en) | 2019-10-04 | 2025-06-03 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| JP2024500880A (ja) * | 2020-12-22 | 2024-01-10 | ヴァンダービルト ユニヴァーシティ | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| WO2022261427A1 (en) | 2021-06-11 | 2022-12-15 | Vanderbilt University | (4-(6-((2-octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-lambda6- sulfanone derivatives and similar compounds as muscarinic acetylcholine receptor m4 antagonists for the treatment of neurodegenerative disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102474326B1 (ko) * | 2016-06-22 | 2022-12-05 | 반더빌트유니버시티 | 무스카린성 아세틸콜린 수용체 m4의 양성 알로스테릭 조절제 |
| AU2018313802A1 (en) * | 2017-08-08 | 2020-02-20 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| JP7270989B2 (ja) * | 2017-10-20 | 2023-05-11 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| WO2021119254A1 (en) * | 2019-12-10 | 2021-06-17 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| US20230183219A1 (en) * | 2020-04-24 | 2023-06-15 | Vanderbilt University | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 |
| CA3180717A1 (en) * | 2020-04-24 | 2021-10-28 | Vanderbilt University | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 |
-
2021
- 2021-12-22 CN CN202180087480.8A patent/CN116669737A/zh active Pending
-
2022
- 2022-12-01 CN CN202280088712.6A patent/CN118541365A/zh active Pending
- 2022-12-01 IL IL313219A patent/IL313219A/en unknown
- 2022-12-01 MX MX2024006718A patent/MX2024006718A/es unknown
- 2022-12-01 US US18/715,048 patent/US20250145595A1/en active Pending
- 2022-12-01 JP JP2024532491A patent/JP2024543973A/ja active Pending
- 2022-12-01 WO PCT/US2022/051493 patent/WO2023102100A1/en not_active Ceased
- 2022-12-01 EP EP22843543.4A patent/EP4441046A1/en active Pending
- 2022-12-01 CA CA3241298A patent/CA3241298A1/en active Pending
- 2022-12-01 AU AU2022400780A patent/AU2022400780A1/en active Pending
- 2022-12-01 KR KR1020247021498A patent/KR20240112343A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240112343A (ko) | 2024-07-18 |
| AU2022400780A1 (en) | 2024-06-20 |
| CA3241298A1 (en) | 2023-06-08 |
| US20250145595A1 (en) | 2025-05-08 |
| CN118541365A (zh) | 2024-08-23 |
| CN116669737A (zh) | 2023-08-29 |
| WO2023102100A1 (en) | 2023-06-08 |
| JP2024543973A (ja) | 2024-11-26 |
| EP4441046A1 (en) | 2024-10-09 |
| IL313219A (en) | 2024-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3064093T3 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| BR112015024907A2 (pt) | n-acil-(3-substituido)-(8-substituido)-5,6-dihidro-[1,2,4]triazol[4,3a]pirazinas como antagonistas receptores seletivos de nk-3, composição farmacêutica, métodos para uso em desordens mediadas por receptores de nk-3 | |
| MX374346B (es) | Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4). | |
| CL2009000860A1 (es) | Compuestos derivados de 4-fenil-4-metil-5,6-dihidro-4h-1,3-tiazina-2-amina; composiciones farmaceuticas que los contienen; y uso de los compuestos en la preparacion de medicamentos inhibidores de bace, utiles para el tratamiento de trastornos mediados por esta enzima, tal como la enfermedad de alzheimer. | |
| UY31619A1 (es) | Compuestos espiro como antagonistas del receptor npy y5 | |
| CL2009000873A1 (es) | Compuestos derivados de ciclohepta[b]piridina, antagonistas del receptor de cgrp; composicion farmaceutica; y uso para el tratamiento de la migrana.b | |
| CL2011001263A1 (es) | Compuestos derivados de pirimidinonas opcionalmente sustituidas; composicion farmaceutica que los comprende; y su uso como inhibidores de fosfodiesterasa 1 (pde1) para el tratamiento de enfermedades que involucran trastornos de la trayectoria intracelular del receptor de dopamina d1 como parkinson, alzheimer, depresion, enfermedad bipolar, hipertension, glaucoma. | |
| ECSP13013033A (es) | Derivados de 2-(2,4,5-anilino sustituido)pirimidina como moduladores de egfr útiles para el tratamiento del cáncer | |
| CL2009000975A1 (es) | Compuestos derivados de quinuclidina, ligandos del receptor de acetilcolina a7; su composicion farmaceutica; su uso para el tratamiento de trastornos del sistema nervioso central, en especial afectivos y neurodegenerativos, enfermedades tales como esquizofrenia y alzheimer. | |
| BR112017002260A2 (pt) | derivados de piperazina como moduladores do receptor x do fígado | |
| EA201792374A1 (ru) | Азабензимидазолы и их применение в качестве модуляторов рецептора ampa | |
| ECSP10010429A (es) | Derivados bicíclicos heterocíclicos o espirobicíclicos heterocíclicos enlazados, de pirazolo[1,5-a]pirimidinas, procedimientos para su preparación y usos de los mismos | |
| BR112013021675A2 (pt) | compostos de triazolopiridina como inibidores de pim cinase | |
| BR112015021549A2 (pt) | inibidores de piridina cinase cdk9 | |
| MY167575A (en) | Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases | |
| PE20142301A1 (es) | Uracilos sustituidos biciclicamente y uso de los mismos | |
| CL2018003669A1 (es) | Moduladores alostéricos positivos del receptor muscarínico de acetilcolina m4. | |
| BR112014027117A8 (pt) | Derivados de pirazol aminopirimidina como moduladores de lrrk2, seus usos, e composição | |
| BR112017004459A2 (pt) | composições e métodos para o tratamento de distúrbios de proliferação | |
| MA32622B1 (fr) | Derives de carbonate de quinuclidine et composition medicinale les comprenant | |
| JOP20170099B1 (ar) | شكل متعدد الأشكال من n-{6-(2-هيدروكسي بروبان-2-يل)-2-[2-(مثيل سلفونيل) إثيل]-2h-إندازول-5-يل}-6-(ثلاثي فلورومثيل) بيريدين-2-كربوكساميد | |
| JOP20230128A1 (ar) | مركبات صيدلانية | |
| EA201190017A1 (ru) | Аминоэфирные производные алкалоидов и их медицинские композиции | |
| NZ736055A (en) | Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators | |
| EA201991021A1 (ru) | Соединения конденсированных бициклических пиридинов и их применение в качестве модуляторов ampa-рецептора |